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model was a hospital in the United States (US). Clinical data was obtained from US 
pivotal studies for the Medtronic stent system and the competing stent systems. The 
competition arm (Competition) was created by pooling the pivotal study data for the 
current stent systems manufactured by Gore, Endologix, and Cook. Cost data was 
obtained from the Premier database (2011-2012) and augmented with the published 
literature. All costs were adjusted to 2013 dollars. The model estimated the costs 
associated with the following utilization outcomes: procedure time, transfusion rate, 
intensive care unit (ICU) length of stay (LOS), and general ward LOS. The following 
adverse events were considered: myocardial infarction, respiratory failure, acute 
renal failure, stroke/TIA, and second endovascular procedure within 12 months of 
the initial procedure. Sensitivity analysis was performed to assess the impact of 
imputed data, and one-way sensitivity analysis was performed for each parameter.  
Results: The expected costs for a hospital related to the above utilization and 
adverse event were $8,463 for Medtronic’s stent graft system and $11,380 for the 
Competition. Fifty-six percent of the $2,917 difference was attributable to improved 
utilization associated with Medtronic’s stent graft compared to the Competition. 
Adverse events and secondary endovascular procedures accounted for 25% and 19% 
of the difference, respectively. These results were robust to alternative sensitivity 
analyses. ConClusions: This analysis suggested that Medtronic’s current stent 
graft is associated with cost savings compared to Competition for the above param-
eters. Future research is necessary to examine if these results are maintained based 
upon a head-to-head clinical study of EVAR stent systems.
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objeCtives: ADVANCEIII trial showed that a long detection programming reduces 
all delivered therapies as well as inappropriate shocks in patients implanted with 
implantable cardioverter defibrillator (ICD). The purpose of this Advance III sec-
ondary analysis was to assess the impact of long detection on hospitalizations (H), 
length of stay (LOS) and associated costs for the health care system. Methods: 
1902 patients enrolled in the ADVANCEIII Trial: 948 patients randomized to long 
detection (NID 30/40) and 954 to short setting (NID 18/24). All hospitalizations 
were reviewed and classified according to ICD9CM codes and, consequently, to the 
corresponding Diagnosis-Related Groups (DRGs). Costs correspond to the specific 
public tariffs for the DRGs applied. The prospective was of a single-payer agent 
(Italian Ministry of Health). Results: Over a median period of 12 months, rates 
of overall and cardiovascular hospitalizations (CV) were lower in the long detec-
tion group (43.8*100 pts/years (39.6-48.4) vs 52.3*100 pts/years (47.7-57.3), IRR: 0.84 
(0.73-0.96) p= 0.005,32.7*100 pts/years (29.1-36.7) vs 40.3*100 pts/years (36.2-44.6), 
IRR (95% CI): 0.81 (0.69-0.95) p= 0.004 respectively). Patients programmed with a 
long detection had shorter LOS (overall H: 407days (394-421) vs 470 days (456-484), 
IRR: 0.87 (0.83-0.91) p< 0.001; CV: 298 days (287-309) vs 368 days (356-381), IRR: 0.81 
(0.77-0.85) p< 0.001) and lower mean hospital cost per patient-year compared with 
patients with nominal programming (overall H: 1.311 € (1.309 € - 1.314 € ) versus 
1.528€ (1.525€ - 1.530€ ) IRR: 0.86 (0.86-0.86) p< 0.001; CV: 1.100 € (1.098 € - 1.103 € ) 
versus 1.339 € (1.337 € - 1.342 € ) IRR: 0.86 (0.86-0.86) p< 0.001). ConClusions: 
A long detection window was associated with a reduction in hospitalization rates, 
total length of stay and cost per patients both for all-causes and cardiovascular 
related events.
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objeCtives: The rising cost of treatment of peripheral arterial disease and the 
growing incidence of this disease led to economic analysis of arterial disease. With 
the increasing price of modern instrumentation, it is appropriate to evaluate not 
only clinical efficiency, but also intervention economics. This study aims to create a 
recommendation for choosing the most effective treatment based on both economic 
data and clinical outputs of the disabled superficial femoral artery. Methods: The 
methods chosen were reviewed from clinical outputs for treatment effectiveness, 
multiple-criteria decision-making for the synthesis of treatment effects, analysis of 
costs at the selected interventions and cost-effectiveness analysis. Results: The 
four clinical outputs used in the study as a criterion by the research of the clinical 
studies were primary patency, technical success, patient survival and limb salvage at 
the year of operation. The weights of each criterion, and the preferences of the inter-
ventions were counted. The sequence of interventions was set by the AHP method: 
PTA (35.6%), PTA/S (33.9%) and bypass (30.6%) and method of weighted sum: PTA/S 
(56%), bypass (55%) and PTA (42%). From the view of both health insurance payer and 
health care provider, where the direct medical expenditures were included, the order 
of intervention was the same: PTA, bypass and PTA/S. The cost-effectiveness was 
calculated for both, and the PTA intervention achieved the best results. Incremental 
expenditures by unit of effect was calculated for each effect: ICER or the domination 
of one intervention over another was set. Ratio of the ICER was generally higher for 
PTA/S compared to bypass. In the sensitive analysis was determined the influence of 
in Acute Kidney Injury (AKI) rate of about 40%. Aim of this study is to perform an 
economic evaluation of GDP strategy with respect to TP in UK and US. Methods: 
A Discrete Event Simulation model was developed to compare TP and GDP strategy 
in patients undergoing CPB. The patient’s pathways from operation to discharging 
from hospital was simulated: AKI incidence, in-hospital mortality, hospital length 
of stay, transfusions were correlated to probability to achieve high DO2 target using 
published correlations. National perspective was adopted to calculate costs asso-
ciated to each event while GDP strategy was exploited considering card and data 
management system (DMS) cost per patient. Results: GDP strategy saved more 
than 3 days in hospital and 11% of AKI episodes. The cost-saving is 2,821 £ in UK 
and 3,206 $ in US; the cost of card and DMS (79 £ in UK, 110 $ in US) is completely 
offset by savings in hospital stay that result the main driver in cost (2,886 £ in UK, 
3,222 $ in US). Deterministic sensitivity analysis shows that the total savings are 
mainly influenced by hospital LOS, cost per day both in ICU and in ward, and nadir 
haematocrit during CPB. ConClusions: GDP seems to improve significantly the 
main outcomes related to CPB surgery, when compared to TP techniques. Additional 
costs due to perform GDP strategy have no impact on the total cost since completely 
offset by the savings in hospital cost.
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objeCtives: The use of polypills in the prevention of cardiovascular disease is 
mooted to reduce costs compared with current practice, yet there is very little 
prospectively-collected data to support this claim. The present study compares 
the ‘real-world’ costs of a polypill strategy against usual care among Australians 
with established cardiovascular disease or at high estimated cardiovascular 
risk. Methods: A ‘within trial’ cost analysis from the Australian health system 
perspective of polypill-based care versus usual care with separate medications 
was conducted using data from the pragmatic randomised controlled trial Kanyini 
Guidelines Adherence to Polypill (Kanyini GAP) and linked health service and medi-
cation claims data. The primary outcome, estimated with generalised linear models, 
was mean health service and pharmaceutical expenditure, per patient per year. 
All costs during the trial, conducted from 2008-2012, were inflated to $AUD 2012 
prices. Results: A statistically significantly lower mean pharmaceutical expendi-
ture of $989 (95%CI 648 to 1331) per patient per year in the polypill arm compared 
to usual care (P< 0.001, adjusted, excluding polypill cost). No significant differences 
were observed in annual non-hospital health service expenditure ($40, 95%CI -202 to 
281 per patient). ConClusions: This study provides evidence that a cardiovascular 
disease polypill strategy has the potential to produce significant cost-savings to 
health systems. At an estimated reimbursement cost of $1 per day for the polypill, 
these savings would have amounted to over $600 per patient per year. Cost-savings 
would accrue to patients also, given fewer prescription charges. Linking health 
service and medication claims data with data from a pragmatic randomised con-
trolled trial has provided an avenue to assess the real-world cost implications of 
introducing this new technology into clinical practice.
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objeCtives: There is a growing prevalence of diabetes mellitus (DM) among chronic 
diseases in the world. Currently there are over 135 million people with diabetes 
worldwide with estimates reaching 300 million in 2025. Developing countries con-
centrate two thirds of these patients and it is known that the economic burden of 
chronic diseases generate high costs for the health system and social welfare as 
a function of mortality and premature disability. The objective of the study was to 
investigate the impact on hospital costs of treating a patient with ischemic heart 
disease and DM, compared with cardiac patients without DM, in a cardiology hospi-
tal of high complexity Ministry of Health in Brazil. Methods: observational study 
of historical cohort of 421 diabetic heart disease (CD) and non diabetic (CND), from 
January 2009 to March 2010 in cardiology hospital of high complexity of the Unified 
Health System (SUS) in Brazil. Were only covered the direct medical costs of hos-
pitalizations. The costs of the study population (CD and CND) were grouped into 
surgery, and clinical treatment obtained by two different approaches (top-down and 
bottom-up estimates), and subsequently analyzed and compared using R software 
version 3.0. Results: No differences between groups were observed. Cost of sur-
gery: CND = U. S. $ 2937.55 and U. S. $ 3024.51 = CD (p = 0.319). Medical Treatment: 
CND = U. S. $ 685.09 and U. S. $ 304.11 = CD (p = 0.218). Values are expressed as 
medians. ConClusions: studies analyzing these conditions separately describe 
high expenses resulting from the treatment of diabetes and cardiovascular disease. 
We can infer from the results of this study that the diabetic patient cardiac does not 
generate a significant financial impact for a cardiology hospital of high complexity.
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objeCtives: To perform a cost comparison analysis of Medtronic’s current stent 
graft system compared to currently competing stent graft systems for endovas-
cular aneurysm repair (EVAR) of abdominal aortic aneurysms (AAA). Methods: 
A simulation model was constructed using Microsoft Excel. The perspective of the 
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greater LOS and 32.3% greater ICU LOS (both p< 0.001) than patients not receiving 
blood. In patients who received blood, total cost of hospital stay was 22.7% greater 
including blood product cost and 21.7% greater excluding blood product cost (both 
p< 0.001). ConClusions: Preventing or rapidly controlling bleeding in patients 
undergoing complex cardiac surgery would likely reduce patient risk and avoid 
elevated costs of hospitalization.
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objeCtives: Syncope, defined as a transient loss of consciousness that leads to a 
spontaneous recovery without consequences, is very prevalent. It is known that syn-
cope related admissions (principal diagnosis) are associated with a high cost burden 
for the Spanish National Health System, but little is known about the number of 
hospitalisations due to injuries caused by the fall (secondary diagnosis). The objec-
tive of this study was to estimate the burden and cost of syncope from the Spanish 
Health Care System perspective. Methods: Admissions with a primary diagnosis 
of syncope and admissions for injuries and pacemaker/defibrillator implantations 
where syncope was coded as a secondary diagnosis were analysed. The source of 
data was the Spanish Basic Minimum Data Set and the period 2001-2010. Results: 
The annual incidence of syncope-related admission was 4.22 cases/10,000 inhab. 
The annual average number of admissions was 15,703, including 77.5% syncope as a 
primary diagnosis. The total annual cost of syncope related admissions was € 46mill, 
from which a 46.4% was associated to injuries where syncope was coded as a sec-
ondary diagnosis. The average cost of a patient admitted with syncope as a primary 
and secondary diagnosis was € 2,062 (min € 1,556 – max € 28,772) and € 5,996 (min € 719 
– max € 26,940) respectively. The average length of stay for patients with syncope as a 
primary and secondary diagnosis was 5.17 and 9.33 days respectively. ConClusions: 
Syncope has an important cost burden resulted from the high number of hospitalisa-
tions and the length of stay associated. The cost of a patient admitted with syncope 
as a secondary diagnosis was nearly 3 times higher than a patient with a primary 
diagnosis of syncope. It is important to implement health strategies to diagnose 
these patients in order to assure an efficient management of the available resources.
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objeCtives: The present study aimed to investigate the cost of non-valvular atrial 
fibrillation (NVAF) management in Hong Kong. Methods: We analyzed consecu-
tive patients with documented NVAF enrolled in the Prince of Wales Hospital Atrial 
Fibrillation Registry between February 2013 and February 2014.. Patient clinical char-
acteristics, prescribed therapies and adverse clinical events were extracted from the 
hospital electronic Clinical Management System. One-year direct health care costs 
including costs of medications, accident and emergency admissions, hospitalizations, 
clinical visits, coagulation tests and computed tomography of brain scans were esti-
mated from a health care provider perspective. Results: Of 534 NVAG patients, 45.9% 
were male with a mean age of 75.8±10.2 years. The average CHADS2, CHAsDSsVASc 
and HASBLED scores were 2.44±1.39,4. 12±1.77 and 3.26±1.09, respectively. 66.7% of 
patients were taking rate control medications only. Patients taking both rate and 
rhythm control medications were associated with the highest rate of hospitaliza-
tions due to poor AF control (28.2%) when compared to using neither rate or rhythm 
control drugs, rate control or rhythm control groups (p < 0.0005). The overall use of 
anticoagulants including both warfarin and new oral anticoagulants was 66.9%. The 
main reason for patients with CHADS2 score ≥ 2 not receiving anticoagulant was 
patient refusal (20%) and physicians’ opinion (40%). The one-year median cost of 
managing patients with stroke was higher than those without stroke (Euro$ 5521.2 
versus Euro$ 1075.2) from the health care provider perspectives during the study 
period. ConClusions: Majority of NVAF patients in Hong Kong were prescribed 
rate control medications only. The clinical use of antithrombotic therapy for stroke 
prevention was more conservative than guideline recommendations. It was more 
costly (5 times more) to manage patients with stroke than patients without stroke.
PCV64
tHe eConomiC imPaCt of CardioVasCUlar eVents in Patients Post 
myoCardial infarCtion: UK HealtH Care PersPeCtiVe
Jain M.1, Sonathi V.1, Rathi H.1, Thomas S.K.2, Mollon P.3
1Novartis Healthcare Pvt. Ltd., Hyderabad, India, 2Novartis Pharmaceuticals Corporation, East 
Hanover, NJ, USA, 3Novaris Pharma AG, Basel, Switzerland
objeCtives: There is a high risk of recurring cardiovascular (CV) events in patients 
post myocardial infarction (MI) despite the current standard of care (SoC). The aim 
of this study was to estimate the current economic burden of CV events for patients 
after having an MI event. Methods: A lifetime markov model was developed from 
a UK health care perspective to capture progression post-MI. Recurrent MI, stroke 
and CV deaths were the major CV events captured. A comparison of cost (2012 UK£) 
and outcomes in terms of QALYs and life years (LYs) was made between the cur-
rent scenario of patients receiving SOC and a hypothetical scenario where post-MI 
patients had no subsequent CV events. All cost and outcomes were discounted at 
3.5% per annum. Results: The current cumulative lifetime event rate of non-fatal 
MI, non-fatal stroke and CV death post-MI was estimated to be 0.432,0. 06 and 
0.42/patient respectively. The total lifetime cost was estimated to be £6,926/post-MI 
patient without CV events, which was 31% lower than the current estimated cost 
of £9,959/post-MI patient. At current rates of CV events there was an incremental 
lifetime loss of 4.3 LYs/patient and 3.5 QALYs/patient when compared to the hypo-
thetical scenario where patients had no CV events. Considering the prevalence of 
MI to be 1.5 million, the economic burden posed by MI patients over lifetime if they 
the direct medical expenditures on the final outputs. ConClusions: The treatment 
of disabled superficial femoral artery was compared from chosen clinical outputs, 
economic expenditures and cost-effectiveness. On this basis, the recommendation 
was set for choosing the most effective treatment.
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objeCtives: Stroke generates an important socioeconomic burden and heavy 
hospital expenses. The objective of this study was to evaluate the impact of delay 
to manage stroke for patients transported by Mobile Intensive Care Units (MICU) 
in outcomes and early hospital costs. Cost of management and NHISS (National 
Institute of Health Stroke Score) score regression at patient discharge have been 
described for three different stroke management time groups. Methods: A retro-
spective study was conducted from a database containing records of 427 patients 
diagnosed with stroke. Patients were classified as “short delay” (stroke managed 
within 45 minutes), “medium delay” (45 minutes to 2 hours) and “long delay” (above 
2 hours). 3 homogenous groups of 100 patients were established, adjusted on age, 
gender, stroke mechanism (ischemic or hemorrhagic), NIHSS score and comorbidity. 
Hospital Database (PMSI - French National Hospital Information Systems Program) 
recorded information between 2004 and 2013. ResultsThe number of deaths was 
respectively 17 for « short delay », 25 for « medium delay » and 42 for « long delay ». 
The average cost for one hospital stay for stroke was € 15,812 for the « short delay 
» group, € 20,639 for « medium delay » and € 20,184 for « long delay ». “Short delay” 
treated patients retrieve an average of 8.41 points compared to 1.87 for “long delay” 
patients. ConClusions: These results show a correlation between the delay in 
managing stroke and early hospital costs and improvement of NIHSS scores. These 
results are part of a study performed through the PMSI database aiming at calculat-
ing the average cost of retrieving one-point NIHSS impairment. They underline the 
importance of an early treatment of stroke.
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objeCtives: Atrial fibrillation (AF) is associated with numerous cardiovascu-
lar (CV) complications. The objective of this study was to estimate the national 
annual burden of CV complications in patients with AF in hospitals. Methods: 
All patients hospitalized in 2012 with a diagnosis of AF were identified from the 
French National public/private hospital database (PMSI). Comorbidities and medical 
data were collected during a 5-year look-back period and used to calculate stroke 
risk score (CHA2DS2-VASc). Reasons for CV-related hospitalization, emergency 
admission, rehabilitation and death at discharge were described. Costs of acute 
care were determined using Diagnosis Related Groups and corresponding tariffs 
(2012 Euros). Results: In total, 533,044 AF patients were hospitalized for any rea-
son. Mean age was 78.0(±11.4) years, 53% were males and mean CHA2DS2-VASc 
score was 4.0(±1.8). CV-related hospitalizations occurred in 267,681 patients: 34% 
for AF management care, 28% for heart failure, 8% for strokes, 7% for other ischemic 
heart diseases, 5% for vascular diseases, 4% for transient ischemic attacks and 
systemic embolisms, 2% for bleedings and 12% for other CV reasons. In CV-related 
hospitalizations, 45% of patients required emergency admission, especially patients 
hospitalized for strokes (75%) and for bleedings (67%). Death at hospital occurred in 
6% of patients with a CV-related hospitalization: 17% in patients with strokes and 
10% in patients with bleedings. Rehabilitation was needed for 34% patients with 
non-fatal strokes with a mean length of 48 days. The annual total cost (acute care 
and rehabilitation) for all hospitalized CV events during the year 2012 was € 1.94 bil-
lion. Among this, heart failure represented € 518m, AF management € 306m, strokes 
€ 291m and hemorrhages € 48m. ConClusions: A half-million AF patients were 
hospitalized in 2012 in France. CV-related hospitalizations involved over a quarter-
million AF patients for a global burden of almost € 2 billion.
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objeCtives: In complex cardiac surgery there is a high demand for blood/blood 
products. Their administration can be costly. Our goal was to assess the cost of 
care and outcomes for complex cardiac surgery patients based on bleeding sta-
tus. Methods: Patients > 18 years, discharged between January 2010 and December 
2012, were identified in the Premier Hospital Database based on ICD9 codes and 
categorized as having received blood/blood products or not. Patients who received 
blood products prior to the day of surgery were excluded. Differences in treatment 
costs and outcomes were assessed using univariate analysis and multivariate mod-
eling. Results: A total of 463,734 patients (82,832 Bleeding; 380,902 Non-Bleeding) 
were included. Patients who received blood were older (> 65 years: 62.3% vs. 49.8%), 
sicker (Charlson Comorbidity Index > 3: 22.5% vs. 15.4%), with greater rates of cer-
ebrovascular disease (10.2% vs. 4.3%), PVD (18.2% vs. 9.4%), CHF (33.0% vs. 18.6%), 
renal dx (20.9% vs. 13.5%) and CPD (25.3% vs. 18.7%) than those who did not. Models 
adjusting for patient factors showed that patients who received blood were 4.54 
times as likely to be admitted to the ICU, 3.40 times as likely to die and 4.59 times as 
likely to be readmitted for bleeding within 30 days (all p< 0.001). They also had 49.1% 
